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ABSTRACT
This study was aimed to understand differences of ondansetron serum concentration 
in each antiemetic responses, polymorphisms of 5HT3B receptor, CYP2D6 and ABCB1 
genes in Indonesian cancer patients treated with high emetogenic cytostatics. We recruited 
cancer patients in Dr Sardjito Hospital treated with cisplatin (≥ 50 mg/m 2) as monotherapy 
or combination therapy. Patients were treated with ondansetron 8 mg intravenously and 
dexamethasone 8 mg intravenously and metoclopramide (10 mg orally) after cytostatic 
administration until 5 days after chemotherapy. We cathegorized the nausea and vomiting 
grade according to the National Cancer Institute Common Toxicity Criteria v.3. We also 
determined some SNPs of ABCB1, 5HT3B and CYP2D6 genes using realtime PCR. We 
recruited 191 cancer patients in this study with the average of ondansetron serum 
concentration reached 33.48 ng/ml (SD: 18.54). According to the patients’ response to 
the antiemetic, during the acute phase, 21.8% patients experienced acute nausea and 
30.2% patients experienced acute vomiting. Only the haplotype of CTG-CTG of ABCB1 
which have significant association with ondansetron serum concentration. EM patients of 
CYP2D6 and patients with haplotype of delAG of 5HT3B had lower ondansetron serum 
concentration. However, IM patients of CYP2D6 showed higher ondansetron serum 
concentration and lower grade of nausea and vomiting. Variations of ABCB1, CYP2D6 
and 5HT3B may be used as pharmacogenetic marker in predicting antiemetic response in 
cancer patients receiving highly emetogenic cytostatic.
ABSTRAK
Penelitian ini bertujuan untuk mengetahui perbedaan konsentrasi ondansetron  serum 
dalam setiap respon antiemetik, polimorfisme gen reseptor 5HT3B , CYP2D6 dan ABCB1  
pada pasien kanker yang mendapatkan sitostatika emetogenik tinggi di Indonesia. Subjek 
dalam penelitian ini adalah pasien kanker di RSUP Dr Sarjito Hospital yang mendapatkan 
terapi sisplatin (≥ 50 mg/m 2) baik sebagai terapi tunggal maupun kombinasi. Subjek 
mendapatkan terapi ondansetron 8 mg, iv dan deksametason 8 mg, dan metoklopramid 
setelah pemberian sitostatika sampai hari kelima kemoterapi. Kategori mual muntah 
berdasarkan National Cancer Institute Common Toxicity Criteria v.3. Beberapa SNPs pada 
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gen ABCB1, 5HT3B dan  CYP2D6 diidentifikasi dengan metode realtime PCR. Sejumlah 
191 pasien berpartisipasi dalam penelitian ini dengan rerata konsentrasi ondansetron 
dalam serum adalah 33.48 ng/ml (SD:18.54). Pasien yang mengalami fase akut mual 
adalah 21.8% dan yang mengalami fase akut muntah adalah 30.2%. Haplotype CTG-
CTG dari ABCB1 mempunyai hubungan yang signifikan dengan kadar indansetron dalam 
serum. Pasien dengan fenotipe EM dari CYP2D6 dan pasien dengan haplotipe delA dari 
5HT3B mempunyai kadar ondansetron rendah dalam serum. Pasien dengan fenotipe IM 
dari CYP2D6 mempunyai konsentrasi ondansetron tinggi dan tingkat mual dan muntah 
yang rendah. Variasi gen ABCB1, CYP2D6 dan 5HT3B dapat digunakan sebagai penanda 
farmakogenetik untuk mengetahui respon antiemetik pada pasien kanker yang menerima 
sitostatik emetogenik tinggi.
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INTRODUCTION 
Nausea and vomiting is the most 
distressfull side effect of chemotherapy in 
cancer patients.1,2 These symptoms may 
affect patient’s quality of life and furthermore 
cause the decrease of patients’ adherence in 
following the chemotherapy treatment.3 In 
cancer patients treated by high and moderate 
emetogenic cytostatic as chemotherapy 
agent, the antiemetic which should be 
given to the patients are combination of 
5-hydroxytriptamine 3 receptor antagonist 
(HT3RA), dexamethasone and neurokinin 
1 receptor antagonist (NK1 antagonist).4,5 
However, around 30% of patients receiving 
high emetogenic cytostatic and  moderate 
emetogenic cytostatic still did not have good 
response to this combination treatment.4 
One of the causal of response variabilities 
of the antiemetic is the polymorphisms of 
5-HT3B receptor, CYP2D6 and ABCB1 genes. 
Even some previous studies did not show the 
consistency about the significancy of statistical 
results, however the pattern of the genotypes 
and the patients’ response were similar.6-10 
One of the previous study supported that 
the polimorphism of CYP2D6 resulted the 
significant difference of tropisetron serum 
concentration in poor metabolizer, extensive 
metabolizer and ultra-rapid metabolizer.8 
This study is aimed to evaluate the 
association between ondansetron serum 
concentration and the antiemetic responses, 
polymorphisms of 5HT3B receptor, CYP2D6 
and ABCB1 genes in Indonesian cancer patients 
treated with high emetogenic cytostatics.
MATERIALS AND METHODS
Patients
We recruited cancer patients in Dr Sardjito 
General Hospital, Yogyakarta who were treated 
with cisplatin (≥ 50 mg/m2) as monotherapy or 
combination therapy. The standard antiemetic 
were  ondansetron 8 mg intravenously and 
dexamethasone 8 mg intravenously. Patients 
were treated with metoclopramide (10 mg 
orally) after cytostatic administration until 
5 days after chemotherapy. The inclusion 
criteria were patients with age  ≥ 18 years 
old and they have a Karnofsky Performance 
Scale (KPS) of ≥ 50%. The patients were 
excluded  if nausea or vomiting were present 
24 hours before chemotherapy; the use of 
other antiemetics such as benzodiazepines or 
neuroleptics, radiotherapy within 24 hours 
before start of chemotherapy, use of opioids 
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within the last 2 weeks,  use of inducers of 
CYP3A4 or inhibitors of CYP2D6, patients 
with concomitant diseases that might cause 
nausea or vomiting, patients with AST-
ALT > 2,5 x ULN for patients without liver 
metastases > 5 x ULN for patients with liver 
metastases, renal dysfunction defined by 
creatinine clearance < 60 ml/minute, brain 
metastases and patients with artificial stoma 
or pregnancy.8,9 We did the informed consent 
to all of the patients before the recruitment. 
This study has been approved by The Medical 
and Health Research Ethics Committee of 
the Faculty of Medicine, Universitas Gadjah 
Mada, Yogyakarta, Indonesia. 
Measurement of nausea and vomiting
We evaluated the nausea using 0-100 
of Nausea Visual Analog Scale (NVAS) for 
5 days after chemotherapy. The vomiting 
was assesed by quantifying the number of 
vomiting that was separated at least 1 minute 
betweeen each of vomiting episode.9
Study outcome definitions
We cathegorized the nausea and vomiting 
according to the previous study. The nausea 
and vomiting were grouped into grade 1-2 
and grade 3-4 nausea vomiting of the National 
Cancer Institute Common Toxicity Criteria 
v.3 (NCI CTC v.3).9,11   
Ondansetron serum concentration assay
The blood was taken from vena mediana 
cubiti 1.5 hour after intravenously injected 
to the patients. The ondansetron peak 
serum concentration reaches 30 ng/ml on 
the administration of 8 mg ondansetron 
intravenously.12 Ondansetron serum 
concentration was measured using High 
Performance Liquid Chromatoghraphy as 
described in the previous method.13,14 
Genotyping assay
We used patients’ saliva as the samples. 
DNA concetration was measured using 
Nanodrop and the genotype assays were 
established using pre-designed Taqman 
assays and analysed on ABI 7500 realtime 
PCR System from Applied Biosystems. 
We also calculated the Hardy-Weinberg 
equilibrium and all of the assay were on the 
Hardy Weinberg equilibrium.
SNPs selection
We used three SNPs in the 5-HT3B 
receptor gene: rs3831455 (deletion AAG 
in 5’-UTR position), rs4938058 (intron) , 
and  rs7943062 (3’ near gene); three SNPs 
in the ABCB1 gene: rs1045642 (exon 26), 
rs2032582 (exon 22), rs 1128503 (exon 
12) and three SNPs of CYP2D6; rs16947 
(CYP2D6*2), rs3892097 (CYP2D6*4), 
rs1065852 (CYP2D6*10). Those particular 
SNPs were selected from the National Center 
for Biotechnology Information SNP database 
using these criteria: a minor allele frequency of 
>0.2, a validated SNP according to the NCBI 
database, and preferably a perfect Linkage 
Disequilibrium (LD) with other SNPs (for 
5-HTR3B receptor gene: D’- =1 and r-square 
≥0.7) and/or indications for relevance based 
on previous publications.6,8-10
Statistical analysis
The student-t test was  performed 
to understand the differences between 
ondansetron serum concentration. We 
performed haplotype frequency estimation 
and individual haplotype from genotype data 
using gPlink.  The metabolizer’s phenotypes 
of SNPs of CYP2D6 were defined according 
to the previous study, as CYP2D6*2, *4 and 
*10.9
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TABLE 2 shows the differences between 
CYP2D6 phenotypes, nausea and vomiting 
grades and ondansetron serum concentration. 
There were no significant asssociation among 
RESULTS
We recruited 191 cancer patients in this 
study. The mean age of patients was 48.23 
± 9.7 years  and most of them were female 
(93.1%). Around 58 % patients were diagnosed 
as cervical cancer , around 67 % of them were 
in the early stage and around 90% patients 
were treated with cisplatin (50-70 mg/m2) 
either as  monotherapy or in combination. We 
found that the average of ondansetron serum 
concentration reached 33.48 ± 18.54 ng/mL. 
This infomation is in line with the literature 
which reported that after 1.5 treatment 
of ondansetron intravenously, the peak 
ondansetron concentration will reach 30 ng/
mL.12 According to the patients’ response to 
the antiemetic, during the acute phase, 21.8% 
patients experienced acute nausea and 30.2% 
patients experienced acute vomiting.
Characteristic Value %
Ondansetron serum concentration (ng/mL)
     Mean ± SD 33.48 ± 18.54
     Minimal concentration 0.18
     Maximal concentration 117.36
Age 48.2 ± 9.7
Sex
     Male 13 6.8
     Female 178 93.2
Diagnosis
     Cervical cancer 112 58.6
     Ovarian cancer 57 29.8
     Others 22 11.6
Stage of cancer
     Stage I and II 128 67.0
     Stage III and IV 63 33.0
Cytostatic agent
     Cisplatin 76 39.8
     Cisplatin and other agent 115 60.2
Cisplatin dose
     50-70 mg/m2 173 90.6
     75-100 mg/m2 18 9.4
TABLE 1.  Characteristics of cancer patients treated with antiemetics 
 (n = 191)
them. However, we can see that EM patients, 
patients with higher grade of nausea and 
patients with lower grade of vomiting had 
lower ondansetron serum concentration. 
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TABLE 3 lists the differences between 
ondansetron serum concentration and 
haplotype of 5HT3B  and ABCB1 genes. 
FIGURE 1 shows the ondansetron 
serum concentration in the vomiting grades 
and CYP2D6 phenotypes. In EM patients, 
serum concentration of ondansetron are 
higher in subjects with grade 2 and 3 
vomiting than subjects with grade 0 and 1 
Cathegory
Ondansetron serum concentration
p value
n Mean  ±  SD
CYP2D6 phenotype
     EM 165 33.30 ± 18.96 0.862
     IM 23 34.02 ± 14.83
Nausea grade
0 and 1 150 33.62 ± 18.14 0.850
2 and 3 41 32.99 ± 20.18
Vomiting grade
0 and 1 135 32.26 ± 17.94 0.1582 and 3 56 36.43 ± 19.77
TABLE 2.  Differeces between ondansetron serum concentration and CYP2D6 
phenotypes, nausea  and vomiting grade 
vomiting. In contrast, among the subjects 
with IM phenotype, serum concentration of 
ondansetron are higher in subjects with low 
grade of vomiting than subjects with high 
grade of vomiting.
FIGURE 1.  Serum concentration of ondansetron in CYP2D6 
phenotypes and vomiting grades
The significant difference of ondansetron 
concentration is shown in the variant of 
ABCB1 CTG haplotype. Subjects with CTG-
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CTG haplotype had lower ondansetron 
concentration than subjects with other 
haplotype. The subjects with delAG-delAG 
variant of 5HT3B had lower concentration 
of ondansetron than subjects with other 
haplotype.  
Cathegory
Ondansetron serum concen-
tration p value
n Mean ± SD
ABCB1 CCG
     Carriers of other haplotype 160 33.05 ± 18.54
0.624     CCG-CCG 19 35.24 ± 18.11
ABCB 1 CTG
     Carriers of other haplotype 168 33.86 ± 18.75
0.-015     CTG-CTG 11 24.42 ± 10.26
ABCB 1 TTT
     Carriers of other haplotype 160 32.89 ± 18.16
0.405     TTT-TTT 19 36.63 ± 21.33
5-HT3BR  AAGAG
     Wildtype 44 35.01 ± 23.67
0.674     Carriers  of  AAGAG 134 33.65 ± 16.65
5-HT3BR  AAGAG
    Carriers of other haplotype 119 33.59 ± 18.94
0.684     AAGAG-AAGAG 59 34.80 ± 17.91
5-HT3BR  AAGGG
     Carriers of other haplotype 172 33.99 ± 18.77
0.973     AAGGG-AAGGG 6 33.73 ± 12.43
5-HT3BR  AAGAA
     Carriers of other haplotype 176 34.17 ± 18.57
0.225     AAGAA-AAGAA 2 18.10 ± 12.88
5-HT3BR  delAG
     Carriers of other haplotype 172 34.01 ± 18.43
0.934
     delAG--delAG 6 33.37 ± 24.16
TABLE 3.  Differences between ondansetron serum concentration and haplotypes of 
5HT3B and ABCB1 genes 
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DISCUSSION 
Our present study was aimed to understand 
the differences between the polymorphisms 
of 5HT3B, CYP2D6 and ABCB1 genes 
and ondansetron serum concentration. Our 
preliminary data cannot show significant 
differences between the variables. However, 
we can present some pharmacogenetic markers 
which could affect the antiemetic response. 
Around 30% patients did not show good 
response to the ondansetron. The previous 
studies with almost similar regimen without 
NK1 antagonist also showed that the complete 
response of 5HT3RA reached around 70%.2,15 
In the future, Indonesia Health Institute 
should consider the use of NK1 antagonist in 
the guideline of prevention of chemotherapy-
induced nausea vomiting in cancer patients 
treated with highly or moderately cytostatic 
agents.
As seen in the patients’ characteristics, 
cervical cancer was the most diagnosed cancer 
in this study. This fact is in accordance with 
the statistic data on 2014 which was stated 
that the cervical cancer was the 2nd most 
frequent cancer in female and the 2nd most 
frequent cancer as well in the age range of 15-
44 years old.16 Cisplatin was mostly used in 
combination which may have the increase of 
CINV severity. This situation may prolong the 
existence of CINV in to the delayed phase.17 
Thus, the use of antiemetics should be closely 
monitored to increase patients’ compliance in 
the treatment of chemotherapy. 
In this study, we did not find patients 
with ultra rapid metabolizers phenotype 
of CYP2D6. However, we found that EM 
patients had lower serum concentration of 
ondansetron than IM patients. Over the IM 
patients, patients who experienced lower grade 
of nausea and vomiting showed higher serum 
concentration of ondansetron. This result is 
supported by previous study using tropisetron 
which showed that patients with higher 
number of active alleles experienced more 
nausea and vomiting and showed the lower 
serum concentration of tropisetron.8 The other 
previous study with polymorphisms of OCT1 
also supported this finding. Patients with 
higher number of active allele experienced 
higher grade of nausea vomiting with the 
lower serum concentration of ondansetron 
and tropisetron.14
According to the other two genes, only 
one haplotype of ABCB1 which shows 
significant differences between ondansetron 
serum concentration and the haplotype 
of CTG-CTG. However, related with the 
5Ht3BRA gene, there were 6 patients with the 
haplotype of delAG-delAG had lower serum 
concentration of ondansetron. This finding is 
supported by previous study which stated that 
patients with the del AAG experienced higher 
score of nausea and vomiting.10
Our study has limitation about the number 
of patients. Because the number of variant in 
our study is low, thus we need further study 
with larger sample size to reach the significant 
result of statistical analysis. In our study, even 
though the most of statistical result is not 
significant, but we can show the difference 
patterns which are supported by some previous 
study. 
CONCLUSION 
Variations of ABCB1, CYP2D6 and 
5HT3BRA may be used as pharmacogenetic 
marker in predicting antiemetic response in 
cancer patients receiving highly emetogenic 
cytostatic.
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